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Good Laboratory Practices 
and Safety Assessments:  
Another View 
doi:10.1289/ehp.0901755
In a letter responding to an article by Myers 
et al. (2009), Becker et al. (2009) claimed that 
industry’s Good Laboratory Practices (GLP)-
compliant studies are superior to traditional 
academic peer-review in predicting the risk of 
toxic agents. I have read almost 30,000 experi-
mental, etiologic, and epidemiologic papers 
(most in part), and it is evident that industry 
GLP studies do not report the same risks of 
a chemical when published in peer-reviewed 
studies from academia. This may be explained 
by biases in industry experiments and epidemi-
ology, especially in design, due to the financial 
interests of industry sponsors—some receiving 
billions of dollars in revenue per chemical each 
year. For pharmaceuticals, dozens of published 
reviews show a strong correlation between 
industry sponsor  ship and findings of safety; 
I know of four such strong correlations in 
studies of industrial chemical risks (Bekelman 
et al. 2003; Fagin and Lavelle1999; Swaen and 
Meijers1988; vom Saal and Hughes 2005). 
Becker et al. (2009) relied on a commen-
tary by a former editor at the Nature research 
journals (Jennings 2006) to claim that peer-
review gives inferior data compared with GLP 
studies. Actually, Jennings (2006) wrote about 
improving, not abandoning, peer review. He 
presented data showing that the long-term 
value of scientific papers in neuro  science 
(judged by experts) correlates with the quality 
of the journals in which they were published 
(based on impact factor). That is a cardinal 
finding because industry supports various 
journals and their scientific associations, but 
their GLP studies are rarely published in high-
quality journals (again, based on my readings). 
Evidently, industry’s GLP data are not reliable 
enough to publish, while financial indepen-
dence of authors and editors, as well as peer 
review, are markers of good quality data.
Since the widespread experimental test-
ing frauds at Industrial Bio-Test Laboratories 
(Schneider 1983) and Craven Laboratories 
(U.S. Environmental Protection Agency 
1994), which generated the GLP reforms, 
industry has issued oceans of GLP-compliant 
studies for submission to regulatory agencies. 
Few are submitted for publication, but almost 
all (in my experience) are submitted to jour-
nals that publish many industry-sponsored 
studies.
Critically, industry and their regulatory 
agencies took the opportunity proferred by 
the requirement to comply with GLP to 
exclude almost all academic high-quality, 
non-GLP studies from risk assessments of 
existing chemicals (and the toxicity of new 
agents are primarily evaluated by the parties 
who want to sell it). For existing chemicals, 
I have always found that the effective toxicity 
doses in regulatory (GLP) studies are higher 
than those in the peer-reviewed literature, for 
several end points. 
It is important for individuals who value 
the contributions that science makes to soci-
ety (reliable data)—or those who are cautious 
about toxicity of low-dose and cocktail agents 
that may affect biochemical signals, especially 
during development—to continue lobby-
ing public agencies to incorporate academia’s 
peer-reviewed studies and to use disclosure 
of financial interests to give appropriate cre-
dence to industry’s data in chemical risk 
assessments. I also call on independent aca-
demics to be less competitive and make their 
methods and data more freely available. 
The author works for scientists and nongovern-
mental organizations, all of which have financial 
interests that align with public health. 
Tony Tweedale
R.I.S.K. Consultancy
(Rebutting Industry Science 
with Knowledge)
Edinburgh, Scotland 
E-mail: tony.tweedale@phonecoop.coop 
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Good Laboratory Practices: 
Becker et al. Respond
doi:10.1289/ehp.0901755R
We appreciate the dialogue stimulated by our 
letter to the editor (Becker et al. 2009). Our 
intent was to respond only to Myers et al. 
(2009) regarding the purpose and function of 
Good Laboratory Practices (GLP) for weighting 
reliability of studies. Tyl (2009), in response to 
Myers et al. (2009), provided extensive point-
by-point discussion of the specific studies. 
In his letter, Tweedale implies that we 
argued to a priori exclude academic, non-GLP 
studies from risk assessments. To the contrary, 
we clearly stated that “[e]ach study, GLP and 
non-GLP, should be evaluated and weighed 
in accordance with fundamental scientific 
principles” (Becker et al. 2009). We fully 
agree with Tweedale that sources of funding 
should be disclosed, that researchers should 
“make their methods and data more freely 
available,” and more industry-supported stud-
ies should be published in scientific journals. 
With respect to bias, Maurissen et al. (2005) 
and Barrow and Conrad (2006) discussed the 
spectrum of mechanisms in place to ensure 
the integrity of industry-sponsored research. 
Ultimately, all scientific research must stand 
on its merits. However, it is unscien  tific to 
eliminate or devalue any study based solely 
on the organization that conducted the 
study, the affiliation of an investigator, or the 
source of funding. The Society of Toxicology 
(2008) has stated this principle quite clearly:   
“[r]esearch should be judged on the basis of 
scientific merit, without regard for the fund-
ing source or where the studies are conducted 
(e.g., academia, government, or industry).”
Moreover, we did not seek to call into 
question scientific journal peer review per se, 
but instead to point out that whereas all study 
records and data from GLP investigations are 
available to regulatory agencies, rarely are such 
details made available as part of a peer-reviewed 
article published in a scientific journal. The 
point we wish to emphasize is that typical regu-
latory safety assessment studies conducted in 
accordance with GLP a) must follow agency 
test guidelines to assure use of relevant test 
systems, sufficient and applicable dosing pro-
tocols, and adequate dose groups and sizes, 
and b) must evaluate specific end points that 
regulatory organizations consider validated. 
Further, such GLP studies submitted to regu-
latory agencies generally include both a full 
study report and all raw data. This level of sci-
entific rigor and the extensive data of a GLP 
study allow a regulatory agency to conduct a 
comprehensive review and to reach a fully inde-
pendent conclusion. For these reasons, greater 
weight and confidence are generally afforded to 
GLP studies. Now, with the increasingly com-
mon practice of journals providing access to 
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supplemental data, there are expanded oppor-
tunities for researchers to disseminate actual 
study data; this should facilitate independent 
evaluation by regulatory agencies. 
As scientists specializing in regula-
tory safety evaluations, we have extensive 
experience in interpreting chemical toxicity 
studies from government, academia, and private- 
sector laboratories. In conducting chemical 
risk assessments, we believe that scientists from 
all sectors should support the use of objec-
tive criteria for determining data quality and 
study reliability (Schneider et al. 2009) cou-
pled with a structured evaluative framework, 
such as that of the World Health Organization 
International Programme on Chemical Safety 
(Boobis et al. 2006, 2008), to provide a sys-
tematic approach for assessing the overall 
weight of the evidence for observed effects and 
the postulated mode of action. In this manner, 
data from laboratory experiments, epidemio-
logical investigations, and cutting-edge mecha-
nistic research from all relevant studies—GLP 
and non-GLP—and from all investigators, 
regardless of affiliation or funding source, can 
be comprehensively reviewed, given appropri-
ate weight, and integrated in a manner that 
provides a robust, biologically plausible under-
standing of the potential hazards and risks that 
exposures to a substance could pose. 
This letter has been reviewed in accordance 
with the peer- and administrative-review poli  cies 
of the authors’ organizations. The views expressed 
here are those of the authors and do not necessar-
ily reflect the opinions and/or policies of their 
employers. 
The authors are employed by trade associa  tions 
whose members manufacture and use chemicals.
Richard A. Becker 
American Chemistry Council 
Arlington, Virginia 
E-mail: rick_becker@americanchemistry.com
Erik R. Janus 
Crop Life America 
Washington, DC 
Russell D. White 
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ICCVAM: Not Doing Enough
doi:10.1289/ehp.1001969
Anyone interested in the facts about the 
Interagency Coordinating Committee on 
the Validation of Alternative Methods 
(ICCVAM) and its ineffectiveness, rather than 
just another ICCVAM/National Toxicology 
Program (NTP) fluff piece (Birnbaum and 
Stokes 2010), should read the 2008 front page 
Washington Post exposé of ICCVAM (Gaul 
2008) and the PETA report on which the Post 
investigation was based (PETA 2008). 
Birnbaum and Stokes’ “PR piece” 
notwithstanding, ICCVAM should be 
held responsible for failing to abide by 
its Congressional mandate to support the 
develop  ment and implementation of non-
animal testing methods.
Sadly, it appears that the new leadership 
of the National Institute of Environmental 
Health Sciences is no more inclined to 
improve the quality of the science support-
ing regulatory decision-making than the 
previous one.
The author is employed by People for the 
Ethical Treatment of Animals, the largest animal 
rights organization in the world.
Jessica Sandler
Regulatory Testing Division
People for the Ethical Treatment of Animals
Norfolk, Virginia
Email: JessicaS@peta.org
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ICCVAM: Birnbaum and Stokes 
Respond
doi:10.1289/ehp.1001969R
Sandler’s comments about our editorial 
concerning the Interagency Coordinating 
Committee on the Validation of Alternative 
Methods (ICCVAM) (Birnbaum and Stokes 
2010) suggest a lack of awareness of the 
role and significance of the contributions of 
ICCVAM. The 2008 Washington Post article 
she cites (Gaul 2008) contained many inaccu-
rate statements (a letter correcting the errors 
was submitted to the Washington Post, but it 
was not published). We appreciate this oppor-
tunity to provide accurate factual information 
about ICCVAM. 
ICCVAM is a congressionally mandated 
committee that does not have laboratories 
and does not develop test methods or con-
duct validation studies. Rather, ICCVAM 
depends on other organizations, including its 
15 member agencies, to carry out such activi-
ties. The director of the National Institute 
of Environmental Health Sciences (NIEHS) 
established ICCVAM in 1997, with the 
cooperation of 14 other agencies, in order to 
provide a coordinated inter  agency process to 
facilitate the regulatory acceptance of scien-
tifically valid alternative methods. As an inter-
agency forum, ICCVAM also coordinates and 
promotes related issues, including national 
and international harmonization, guidance on 
validation studies, and awareness of accepted 
alternative methods. 
ICCVAM was formally established 
by legis  lation in 2000 with signing of 
the ICCVAM Authorization Act of 2000. 
This law charges ICCVAM to “review and 
evaluate new or revised or alternative test 
methods, … including the coordination of 
technical reviews of proposed new or revised 
or alternative test methods ….” ICCVAM 
develops and submits recommendations based 
on its reviews to the Secretary of Health and 
Human Services for transmittal to federal 
agencies. Agencies must review the recom-
mendations and respond to ICCVAM within 
180 days. ICCVAM has implemented a trans-
parent and scientifically rigorous evaluation 
process for test methods that has resulted in 
national and international regulatory accep-
tance of all recommended test methods. 
ICCVAM has contributed to the acceptance 
of 33 alternative test methods, including 
17 based on formal comprehensive evalua-
tions (ICCVAM 2010). Recommendations 
on an additional 4 methods are pending. 
The National Toxicology Program 
(NTP) Interagency Center for the Evaluation 
of Alternative Toxicological Methods 
(NICEATM) administers ICCVAM and pro-
vides scientific and operational support for 
ICCVAM activities. Consistent with the NTP A 196  v o l u m e 118 | number 5 | May 2010  •  Environmental Health Perspectives
mission, NICEATM also conducts independent 
validation studies on new, revised, and alterna-
tive test methods, and coordinates international 
validation studies with its counterparts in Japan, 
Europe, and Canada (NIEHS 2009).
In 2008, NICEATM and ICCVAM 
launched a 5-year plan to further reduce, refine, 
and replace the use of animals in regu  la  tory 
testing in conjunction with federal agencies and 
other stakeholders (ICCVAM 2008). The plan 
seeks to advance alternative test methods of high 
scientific quality that will continue to protect 
and advance the health of people, animals, and 
the environ  ment. The plan emphasizes using 
new technology to develop predictive systems 
that will lessen or avoid the need for animals 
where scientifically feasible. 
The NIEHS and NTP support research 
that may lead to the development of new 
test methods relevant to regulatory testing.   
These include the Tox21 collaboration between 
the NTP, the National Institutes of Health 
Chemical Genomics Center, and the U.S. 
Environmental Protection Agency (Schmidt 
2009). The Tox21 initiative is the largest in vitro 
toxicology research program ever conducted 
worldwide and is expected to yield candidate 
methods and approaches with potential appli-
cability to regulatory testing. Following stan-
dardization and validation in consultation with 
ICCVAM, methods with regulatory applicabil-
ity will be reviewed by ICCVAM and recom-
mendations forwarded to appropriate agencies. 
ICCVAM has been enormously successful 
in gaining regulatory acceptance of alternative 
methods (ICCVAM 2010). Gaining regula-
tory acceptance requires high-quality studies 
that prove that the alternative test methods 
will provide the same or better level of protec-
tion of workers and consumers as the methods 
they might replace. The test method must 
also be shown to be reproducible in different 
laboratories. 
The animal welfare benefits of ICCVAM’s 
work are evidenced by many examples. These 
include an alternative test for acute oral toxicity 
that has replaced the LD50 test (median lethal 
dose), which used as many as 200 animals per 
test, with the Up-and-Down Procedure (UDP), 
which uses only 7 animals on average per test 
(NIEHS 2001; Organisation for Economic 
Co-operation and Development 2008). The 
UDP and other alternative test methods have 
profoundly reduced animal use for acute oral 
toxicity testing, which is conducted to deter-
mine the poisoning potential of chemicals and 
products and is the most commonly conducted 
safety test worldwide.
Another landmark ICCVAM contribution 
is the reduction and refinement of animal use 
for eye-safety testing. ICCVAM evaluated and 
recommended the first two in vitro test meth-
ods that can now be used to determine whether 
substances can cause blindness and other severe 
eye damage, without the need for live animals 
(NIEHS 2008). Based on ICCVAM’s evalua-
tion, these test methods were adopted as inter-
national test guidelines in 2009.
In summary, ICCVAM has demon  strated 
its effectiveness and value in achieving the regu-
latory acceptance of test methods that reduce, 
refine, and replace animal use. Most impor-
tantly, by making appropriate science-based 
decisions, ICCVAM has ensured that such 
methods will continue to protect the public’s 
health and safety. We expect ICCVAM to serve 
an increasingly important role in translating 
research advances into improved test methods 
that will benefit both people and animals.
The authors declare they have no competing 
financial interests.
Linda S. Birnbaum
Director, NIEHS and NTP
National Institutes of Health
Department of Health and Human Services
Research Triangle Park, NC, USA
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Polyethylene Terephthalate 
and Endocrine Disruptors
doi:10.1289/ehp.1001986
In the commentary “Polyethylene Terephthalate 
May Yield Endocrine Disruptors,” Sax (2010) 
theorized that bottles made of polyethylene 
terephthalate (PET) might leach phthalate ester 
plasticizers and/or antimony to produce endo-
crine-disrupting effects. On behalf of the North 
American producers of PET resin, I have the 
following comments and corrections.
Phthalate ester plasticizers are not used to 
manufacture polyethylene terephthalate and 
never have been. It is not chemically plausible 
for PET to produce these phthalate esters. 
Sax (2010) did suggest that some reports of 
phthalate esters in PET bottled water containers 
may have originated from contamination of the 
bottled water, or from phthalate ester contami-
nation of recycled PET used in manufacturing 
water and beverage containers. In addition, non-
PET components of bottled water containers 
(e.g., closures) might be another possible source. 
Whatever the origin of phthalate esters, which 
could not be identified in any of the studies 
cited by Sax, it is clearly unreasonable to ascribe 
PET as the source.
Regarding antimony, Sax noted that Choe 
et al. (2003) reported antimony chloride as 
showing high estrogenicity. However, anti-
mony oxides—not antimony chloride—are 
used as catalysts in the manu  facture of PET. 
Antimony oxides are chemically and toxico-
logically distinct from antimony chlorides. No 
study has reported finding toxic amounts of 
antimony in PET-bottled water or beverages.
PET bottles and containers meet all appli-
cable U.S. and international safety require-
ments for food contact, and the inert qualities 
of PET define its preferred use for many food, 
beverage, and medical applications. Consumers 
can feel confident about the safety of PET 
food and beverage containers.
We welcome dialogue with researchers 
and regulatory agencies on the chemistry and 
safety of PET resin.
The author is employed as the Executive Director 
of the PET Resin Association, the industry asso-
ciation representing North American producers of 
polyethylene terephthalate.
Ralph Vasami
PETRA (PET Resin Association)
New York, New York
E-mail: rvasami@PETresin.orgEnvironmental Health Perspectives  •  v o l u m e 118 | number 5 | May 2010  A 197
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Polyethylene Terephthalate: 
Sax Responds
doi:10.1289/ehp.1001986R
In his letter Vasami reminds readers that 
phthalates are not used in the manufacture of 
PET. Indeed, I emphasized precisely this point 
in my commentary (Sax 2010), for example, 
when I stated that “phthalates are not used as 
substrates or precursors in the manufacture of 
PET.” Vasami also asserts that “it is not chemi-
cally plausible for PET to produce these phtha-
late esters”; however, I never suggested that 
virgin PET gives rise to phthalate esters via deg-
radation of PET itself. I did cite multiple stud-
ies in which phthalates were recovered from 
the contents of PET bottles—as contaminants 
leaching from the PET bottle wall. How did 
the phthalates come to be there? As I noted, 
one possibility is that some of the PET used 
in manufacturing the bottles may have been 
recycled PET, and some of this recycled PET 
might have been contaminated with phtha-
lates. Again, as I noted in my commentary, 
PET is commonly used for bottling a variety 
of products (e.g. shampoo) that are known 
to contain phthalates; these phthalates can 
then sorb into the PET bottle. Other research-
ers have previously documented that various 
organic substances readily migrate into PET 
(e.g., Komolprasert and Lawson 1997). Indeed, 
previous investigators have documented the 
presence of phthalates in PET bottles marketed 
for consumer use (e.g., Kim et al. 1990); Nerín 
et al. (2000) reported that the concentration of 
phthalates was much higher in recycled PET 
material than in virgin PET. 
There are good environmental arguments 
for recycling plastics rather than disposing of 
them in landfills. The potential for tension 
between the desire to recycle plastics, on the 
one hand, and the desire to protect human 
health, on the other hand, has long been rec-
ognized (e.g., Castle 1994). Reconciling these 
two objectives requires a better understanding 
of the origin of endocrine disruptors in PET.
Vasami notes that although Choe et al. 
(2003) reported antimony chloride as show-
ing high estrogenicity, “antimony oxides—not 
antimony chloride—are used as catalysts in the 
manufacture of PET.” Although Vasami asserts 
that antimony oxides “are chemically and toxi-
cologically distinct from antimony chlorides,” 
the toxicological literature does not provide 
strong support for this assertion. Antimony 
chloride, when combined with water, read-
ily forms antimony oxide (National Research 
Council 2000), and both antimony chloride 
and antimony oxide ionize in vivo. Merski 
et al. (2008) reported that when animals were 
fed ground PET, antimony was recovered 
from their urine in a dose-  dependent fashion. 
Toxicologically, what seems to matter is the 
antimony and its oxidation state [tri  valent (III) 
or penta  valent (V)], not the anion (chloride or 
oxide). Antimony(III) is the ionization state in 
the antimony oxide used in the production of 
PET; the same ionization state (III) is found in 
antimony chloride. Using X-ray spectrometry, 
Martin et al. (2010) confirmed that the anti-
mony in PET bottle walls is in fact trivalent 
antimony. The toxicological literature clearly 
establishes that trivalent antimony is far more 
toxic to humans than is pentavalent antimony 
(e.g., Chulay et al. 1988; De Boeck et al. 2003; 
Phillips and Stanley 2006). Vasami’s implica-
tion that antimony(III) oxide, when ingested, 
might be free of the risks demonstrated for 
antimony(III) chloride, is without evidentiary 
basis.
Vasami concludes by reminding readers 
that PET bottles meet all applicable safety 
requirements. However, he neglects to note 
that these safety requirements were devel-
oped largely in the 1980s and 1990s, when 
the chief concern about antimony and other 
metalloids had to do with carcino  genicity 
(e.g., De Boeck et al. 2003) and organ toxic-
ity (e.g., Poon et al. 1998). The standards 
were developed based on doses believed to be 
carcinogenic and/or directly toxic. The ability 
of inorganic metalloids such as antimony to 
act as xeno  estrogens has only recently been 
recognized (Darbre 2006). More research is 
needed to determine whether the regulatory 
requirements for antimony in foods and bev-
erages should be adjusted in order to mini-
mize the risk of endocrine-disrupting effects.
Certainly there is a paucity of research on 
the endocrine-disrupting effects of antimony. 
But surely the remedy for this deficiency is 
more research, not a stubborn insistence that 
what we don’t know can’t hurt us.
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cial interests.
Leonard Sax
Montgomery Center for Research in Child 
& Adolescent Development
Exton, Pennsylvania
E-mail: mcrcad@verizon.net 
RefeRences
Castle L. 1994. Recycled and re-used plastics for food packag-
ing? Packaging Tech Sci 7(6):291–297.
Choe SY, Kim SJ, Kim HG, Lee JH, Choi Y, Lee H, et al. 2003. 
Evaluation of estrogenicity of major heavy metals. Sci 
Total Environ 312(1):15–21.
Chulay JD, Fleckenstein L, Smith DH. 1988. Pharmacokinetics 
of antimony during treatment of visceral leishmaniasis 
with sodium stibogluconate or meglumine antimoniate. 
Trans R Soc Trop Med Hyg 82(1):69–72.
Darbre PD. 2006. Metalloestrogens: an emerging class of 
inorganic xenoestrogens with potential to add to the 
oestrogenic burden of the human breast. J Appl Toxicol 
26(3):191–197.
De Boeck M, Kirsch-Volders M, Lison D. 2003. Cobalt and 
antimony: genotoxicity and carcinogenicity. Mutat Res 
533(1–2):135–152.
Kim H, Gilbert SG, Johnson JB. 1990. Determinations of 
potential migrants from commercial amber polyethylene 
terephthalate bottle wall. Pharm Res 7(2):176–179.
Komolprasert V, Lawson AR. 1997. Considerations for reuse of 
poly(ethylene terephthalate) bottles in food packaging: 
migration study. J Agric Food Chem 45(2):444–448.
Martin RR, Shotyk WS, Naftel SJ, Ablett JM, Northrup P. 2010. 
Speciation of antimony in polyethylene terephthalate bot-
tles. X-ray Spect; doi:10.1002/xrs.1241 [Online 9 February 
2010].
Merski JA, Johnson WD, Muzzio M, Lyang NL, Gaworski CL. 
2008. Oral toxicity and bacterial mutagenicity studies with 
a spunbond polyethylene and polyethylene terephthalate 
polymer fabric. Int J Toxicol 27(5):387–395.
National Research Council. 2000. Antimony trioxide. In: 
Toxicological Risks of Selected Flame-Retardant 
Chemicals. Washington DC:National Academies Press, 
229–261. Available: http://www.nap.edu/catalog/9841.html 
[accessed 1 February 2010].
Nerín C, Asensio E, Fernández C, Batlle R. 2000. Supercritical 
fluid extraction of additives and degradation products 
from both virgin and recycled PET. Química Analítica 
19(4):205–212.
Poon R, Chu I, Lecavalier P, Valli VE, Foster W, Gupta S, et al. 
1998. Effects of antimony on rats following 90-day expo-
sure via drinking water. Food Chem Toxicol 36(1):21–35. 
Phillips MA, Stanley SL. 2006. Chemotherapy of protozoal infec-
tions. In: Goodman & Gilman’s Pharmacological Basis of 
Therapeutics (Brunton LL, Lazo JS, Parker KL, eds). 11th ed. 
Available: http://www.accessmedicine.com/content.
aspx?aID=947503 [accessed 4 February 2010].
Sax L. 2010. Polyethylene terephthalate may yield endocrine 
disruptors. Environ Health Perspect 118:445–448. 
Erratum
In the article “Using National and Local Extant Data to Characterize Environmental 
Exposures in the National Children’s Study: Queens County, New York” by Lioy et al. 
[Environ Health Perspect 117:1494–1504 (2009)], Shahnaz Alimokhtari was inadvertently 
omitted as an author. The corrected author names and affiliations are listed below.
Paul J. Lioy,1 Sastry S. Isukapalli,1 Leonardo Trasande,2 Lorna Thorpe,3 Michael Dellarco,4 Clifford 
Weisel,1 Panos G. Georgopoulos,1 Christopher Yung,1 Shahnaz Alimokhtari,1 Margot Brown,4 and 
Philip J. Landrigan2
1Environmental and Occupational Health Sciences Institute, University of Medicine and Dentistry, New Jersey–Robert 
Wood Johnson Medical School and Rutgers University, Piscataway, New Jersey, USA; 2Mount Sinai School of 
Medicine, New York, New York, USA; 3New York City Department of Health and Mental Hygiene, New York, New York, 
USA; 4National Children’s Study, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
The authors apologize for the error.